Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Fig. 6

p65BTK inhibition sensitizes NSCLC cell lines scarcely responsive to EGFR-targeted therapy. Cell viability of human p53-null NSCLC cell lines in response to different combinations of BTK and EGFR inhibitors (T0 = time 0; NT = untreated; GEF20 = Gefitinib 20 μM; ERL20 = Erlotinib 20 μM. IBRU20 = Ibrutinib 20 μM; AVL10 = AVL-292 10 μM; RN10 = RN486 10 μM). X-axis crosses in correspondence of T0 values (before starting the treatment); 72 h values are then expressed as the percentage variation relative to the initial cell number. Scale on Y-axis is adapted to the different growth rates shown by each cell line. Data are presented as mean ± SEM. n ≥ 3 independent experiments. * indicates p < 0.05 vs T0 values

Back to article page